Park Medi World Q2 FY27 Revenue Rises 22.8% to ₹510.9 Crore

Park Medi World Limited reported Q2 FY27 consolidated revenue of ₹510.9 crore, up 22.8% year on year. Operating EBITDA rose 47% to ₹120.2 crore, while profit after tax stood at ₹40.4 crore, or 3.3 times the year-earlier level. The results cover the quarter ended September 30, 2026.

What did Park Medi World report for Q2 FY27?

Park Medi World reported revenue of ₹510.9 crore for Q2 FY27, with operating EBITDA of ₹120.2 crore and a 23.5% operating EBITDA margin. The company said revenue increased 22.8% from the corresponding quarter a year earlier, while operating EBITDA grew 47%.

Profit after tax for the September quarter was ₹40.4 crore, stated as 3.3 times the level reported in Q2 FY26. The company announced that its Board of Directors approved the unaudited consolidated financial results for the quarter and half-year ended September 30, 2026, after review by the Audit Committee.

How were the September-quarter results reviewed?

Park Medi World said the consolidated results were accompanied by limited review reports from its statutory auditors. Agiwal & Associates stated in its limited review that the consolidated financial results were prepared in accordance with Indian Accounting Standards and the applicable Listing Regulations.

The limited review did not identify a material misstatement in the disclosed information for the period ended September 30, 2026. A limited review is distinct from a full audit and is commonly issued for quarterly financial statements of listed companies. The disclosure described the results as unaudited, while providing the auditor's review report as an annexure.

The Board also approved the continuation of Kabir Kishin Thakur as a Non-Executive Non-Independent Director under Regulation 17(1D), subject to shareholder approval. The disclosure further noted that the Q2 FY26 comparative figures had not been reviewed or audited.

How does Q2 compare with Park Medi World's recent performance?

Park Medi World's Q2 release followed a Q1 FY27 period in which it reported sales of ₹476 crore, EBITDA of ₹126 crore and net profit of ₹89 crore. The Q1 sales figure was 19.3% higher than ₹399 crore in Q1 FY26, while reported net profit was 34.85% higher than ₹66 crore in the prior-year quarter.

The available quarterly trend shows sales rising from ₹410 crore in September 2025 to ₹460 crore in March 2026 and ₹476 crore in June 2026. Operating profit was ₹126 crore in June 2026, compared with ₹127 crore in March 2026. This provides context for investors assessing the reported September-quarter revenue growth and the operating margin of 23.5%.

What are the operational factors investors will monitor?

Park Medi World operates 14 NABH-accredited multi-specialty hospitals under the Park brand and is described as the second-largest private hospital chain in North India and the largest in Haryana. Its service lines include cardiac care, oncology, orthopaedics and critical care.

The company has stated an ambition to add 1,490 beds in 2026 and reach 5,740 beds by March 2028. Hospital expansion requires investment in facilities, medical equipment and staff before new capacity reaches stable utilisation. As a result, the pace of additions and the associated effect on occupancy, costs and margins remain relevant operating measures alongside revenue growth.

The source also cited international patients as contributing about 30% of Q2 revenue in a separate operational update. For hospital operators, the mix of domestic and international patients, specialty treatments and mature hospitals can influence revenue per occupied bed and profitability. The disclosed Q2 EBITDA margin gives investors a current reference point while the network expands.

Why does the Q2 FY27 update matter for investors?

The Q2 FY27 update matters because it combines revenue growth of 22.8% with a 47% increase in operating EBITDA. EBITDA growth outpaced revenue growth in the reported quarter, and the company recorded a 23.5% operating EBITDA margin. These measures are important for tracking the earnings capacity of a hospital operator that is pursuing a substantial bed-addition programme.

The results were released on November 13, 2026, 44 days after the September 30 quarter-end. Listed companies in India are required to publish quarterly results within 45 days of the quarter end, which placed the stated outer deadline for September-quarter results at November 14, 2026.

Management's Q2 and H1 FY27 analyst and investor conference call was rescheduled from November 11 to November 14, 2026, at 10:00 a.m. IST. Investors will be able to assess management's discussion of financial performance, operating trends and expansion plans alongside the results and investor presentation.

Conclusion

Park Medi World's September-quarter disclosure reported consolidated revenue of ₹510.9 crore, a 22.8% year-on-year increase, and operating EBITDA of ₹120.2 crore, up 47%. The limited review report said the consolidated results complied with the applicable accounting standards and Listing Regulations and did not indicate a material misstatement.

The next disclosed event is the Q2 and H1 FY27 analyst and investor call on November 14, 2026. Investors will watch for management's updates on the planned addition of 1,490 beds in 2026, progress toward the March 2028 capacity target of 5,740 beds, and operational metrics discussed during the call.